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Familial adenomatous polyposis (FAP) is a well-defined autosomal dominant predisposition to the development of
polyposis in the colon and rectum at unusually early ages. The first symptoms of FAP are diarrhea and blood in the
stool. Weight loss and weaknesses occur after the development of advanced tumour. The incidence of the FAP
disorder is one per 10000 newborns. There are high levels of heterogeneity with regard to the number and timing
of the occurrence of polyps. The classical form of FAP is characterized by the presence of more than 100 polyps,
which appear in the second decade of life. The average time of occurrence of polyps is 15 years. The earliest
symptoms of polyposis have been observed in a three-year-old child. The polyps are characterized by large
potential for the development towards malignant tumour. Malignancy can occur from late childhood onwards.
Attenuated adenomatous polyposis coli is characterized by a more benign course of disease in contrast to classical
FAP. The occurrence of FAP is associated with mutations in the APC tumour suppressor gene, which was described
in 1991. The APC gene is located on chromosome 5q21 and is involved in cell proliferation control. A recessive
form of adenomatous polyposis is caused by mutations in the base excision repair gene - MUTYH gene. The MUTYH
gene is involved in repairing DNA lesions as a result of oxidative DNA damage. MUTYH associated polyposis (MAP)
is a predisposition to the development of polyps of the colon but the number of polyps is lower in comparison to
classical FAP. The high risks of cancer observed in these two diseases make them important medical issues.
Molecular studies of colonic polyposis have been performed in Poland for over fifteen years. A DNA Bank for Polish
FAP patients was established at the Institute of Human Genetics in Poznan in which DNA samples from 600 FAP
families have been collected.
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Familial adenomatous polyposis (FAP) accounts for ap-
proximately 1% of all large intestinal tumour diagnoses
[1]. The disease occurs de novo with the frequency of
somewhere between 1 in 8000 to 1 in 10000 births and
the age of disease penetrance varies quite considerably
even between siblings [2]. However, the occurrence of a
large intestine tumour at unusually young ages should
provide a signal to perform a family anamnesis, which
should identify whether this is a hereditary predispos-
ition or not [3]. The occurrence of a single case of the
disease does not rule out a high hereditary predispos-
ition because a given patient may be the first carrier of
the mutation. FAP symptoms occur earlier than in the
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reproduction in any medium, provided the orcancer, Lynch syndrome and generally start to appear in
the second decade of life. Patients have, however been
reported to be as young as 5 years of age and in the
group of our youngest patients, one was only 3 years old
when polyps were diagnosed [4]. The genetic basis of
FAP is the presence of germline mutations in the APC
gene in the case of FAP and in MUTYH gene – in the
case of the recessive form of adenomatous polyposis,
known as MUTYH adenomatous polyposis (MAP) [5].
The APC gene is a tumour suppressor gene that is in-
volved in the control of β-catenin. Loss of APC function
results in the constitutive activation of β-catenin, which
culminates in cellular proliferation [6]. When cellular
proliferation is allowed to occur unimpeded the prob-
ability of mutations occurring increase as the normal
checkpoint controls are over-ridden. This leads to
the accumulation of changes in genetic material andLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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from their normal cellular constraints.
In the case of APC driven tumourigenesis, normally
both alleles need to be lost prior to disease development.
In patients with FAP they have inherited only one intact
allele (i.e. functional copy of APC), which alters the
probability of disease development [7].
History of investigations of the APC gene
FAP was recognised as a heritable pathogenic syndrome
already in the 1920s. In 1972, Gardener syndrome was
described, which is a form of FAP characterised not only
by the presence of hundreds or even thousands of aden-
omatous polyps in the intestine but also of osteomas
and retinal hypertrophy (congenital hypertrophy of the
retinal pigment epithelium - CHRPE). The occurrence of
FAP was associated with the q21-q22 region of chromo-
some 5 on the basis of a large deletion discovered by
cytogenetic analysis as well as research results from
RFLP marker analysis in a patient with Gardener’s syn-
drome with advanced polyp growth in the colon [8]. To-
wards the end of the 1980s, association studies revealed
a region on the long arm of chromosome 5, which
encompassed APC and MCC genes separated from each
other by 150 kbp. In 1991, the following three genes:
DP1, SRP19 and DP2.5 found in the critical region were
investigated in FAP patients. In the case of four unre-
lated FAP patients, four mutations were observed in the
DP2.5 (now known as APC), resulting in premature stop
codons from which one was transmitted from generation
to generation [1]. In the following year 79 FAP patients
were examined and mutations in APC were observed in
67% of them. In a second study 92% of FAP cases, they
were found to harbour mutations leading resulting in
premature truncation mutations of APC [9]. In many
countries, investigations were undertaken to study the oc-
currence of mutations in APC and a database of inherited
and somatic mutations was established in which data from
826 inherited and 650 somatic mutations were collected
[10]. Once APC had been identified, its function was in-
vestigated and found to bind with β-catenin which sug-
gested its participation in cell adhesion [10].
In Poland, a DNA Bank of FAP patient samples was
established in 1997 at the Institute of Human Genetics
(IHG) of the Polish Academy of Sciences (PAS) in
Poznan in cooperation with Polish Polyposis Registry.
Over 1000 DNA samples have been collected in the IHG
PAS in Poznan within the framework of investigations
into genetic susceptibilities for the development of neo-
plastic diseases associated with the presence of polyps in
the gastrointestinal tract. Currently, in the DNA Bank
there are over 1000 DNA samples stored from 700 FAP
patients derived from 600 families. Moreover, material
from risk groups in which no symptoms of the diseasewere observed at registration has also been gathered.
Molecular studies have resulted in the identification of
mutations in APC in 294 families [11-16].
APC structure and APC protein function
APC (adenomatous polyposis coli) is located on chromo-
some 5 in the q21 region and contains 21 exons [17]. A
characteristic attribute of APC is the occurrence of a
large exon 15, which encompasses over 70% of the cod-
ing sequence. The expression of the gene is observed in
all tissues and the mRNA transcript is 8538 nucleotides
long [1,10]. The first exons can form tissue-specific al-
ternative transcripts [18], for example an APC brain spe-
cific gene transcript for which the start codon is located
in the BS (brain specific) exon. Elimination of codon 1,
which encodes the super helix domain, known to be re-
quired for homo- or heterodimerisation, affects protein
product functionality not [17]. Alternative splicing of
exon 9 has been associated with the occurrence of the
attenuated adenomatous polyposis coli (AAPC) [19]. A
similar effect was recorded in one of two families with
mutations at the 3’ end of exon 9 where, in one case, a
modifying effect was observed leading to a milder FAP
phenotype. That evidences suggests that the location of
mutation as well as the effect of alternative splicing ex-
erts an influence on the disease expression.
Another very interesting phenomenon is the differen-
tial splicing out of exons 14 and 15 of APC (which com-
prises nearly 70% of the gene), with the remaining
fragment binding with the 3’ end of the SRPI gene. Ex-
cising exon 14 or 15 results in the development of two
isoforms differing from each other by their ability to
bind microtubules and β-catenin as well as by the 3’ re-
gion which does not undergo translation and can affect
mRNA stability and protein translation [20,21]. An alter-
native gene assembly, in this case, is associated with the
regulation of the APC protein activity and appears to
suggest that it fulfils a number of different functions in
the cell, especially, in the alternative assembly of the
protein where over 75% of exons take part.
The full-length APC protein contains 2843 amino
acids and can be found in the cytoplasm and cell nu-
cleus [[18]. Several proteins have been identified that
interact with the APC protein. These include: DLG pro-
tein, microtubule protein, GSKβ-3, β-catenin, γ-catenin,
p34, Tid56, Axin protein. Interactions with many pro-
teins indicate that the APC protein participates in the
regulation of many cell processes including: cell division,
migration, adhesion and cell fate determination [1]. A
number of functional domains have been identified in
the APC protein. The base domain encompasses amino
acids 2200–2400 [1]. The N-terminal end of the protein,
between amino acids 1 – 171, is involved in oligomerisa-
tion. There are two β-catenin binding sites in the APC
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nucleotide repeats between amino acids 1020 and 1169
and in the region of 20-amino acid repeats between
amino acids 1324 and 2075. Binding with microtubules,
which occurs with increased gene expression, takes place
with the assistance of the fragment encompassing amino
acids 2130–2483. Amino acids 2450–2843 bind with
EB1 protein, while amino acids 2771–2843 bind with
DLG protein [1]. Attempts to identify the region associ-
ated with apoptosis have met with little success, al-
though it has been reported that the expression of the
appropriate APC protein in an intestinal neoplastic cell
line leads to the occurrence of this phenomenon. A
product of the APC gene of 300 kDa mass participates
in the contact inhibition of cell growth in mucous cells
of the large intestine.
Moreover, APC protein also interacts with γ-catenin
and β-catenin. Both proteins bind with a cell adhesion
protein – E-cadherin. Fearon (1997) proposed a model
in which the APC protein participates in signal trans-
duction and via β-catenin degradation affecting the
activity of TCF4 (T-cell transcription factor 4) transcrip-
tion factor (Figure 1) [20]. The protein that regulates the
formation of the APC protein and β-catenin complex is
protein kinase ZW3/GSK3β. Phosphorylation of the
APC protein activates β-catenin binding. The activity of
GSK3β kinase is regulated by DSH protein, which inter-
acts with the protein products of WNT1. APC protein
bound with kinase ZW3/GSK3β is capable of inhibiting
the transcription induced by β-catenin. In the case of
the loss of the APC gene product the transcription factor
TCF4 (TCF7L2) becomes constitutively activated. Cells
are stimulated to proliferate following activation of
c-MYC by TCF4 [22]. The product of c-MYC resides in
the cell nucleus and is capable of binding with DNA,
activating a series of growth- associated genes that in-
clude ornithine decarboxylase (ODC1) and CDC25A. In
addition, c-MYC inhibits GAS1. It was further shownFigure 1 Role of the APC protein in cell cycle regulation.that the activated β-catenin-TCF4 complex induces
TCF1 expression [23]. In the large intestinal mucous
cells APC serves as a negative regulator of the cell cycle
via the regulation of β-catenin, which is normally acti-
vated by a proliferation signal derived from the trans-
membrane protein E-cadherin. When APC is lost the
balance between cell division and apoptosis in the tissue
becomes disturbed which results in uncontrolled cellular
proliferation.
Mutation of the APC gene
The development of molecular studies was triggered in
1991 by the discovery of the relationship between APC
mutations and FAP. Over the past 11 years, the develop-
ment of various techniques followed by increased num-
bers of publications has occurred in a growing number
of countries and ethnic groups.
Investigations performed over several years using such
techniques as single-stranded conformational poly-
morphism (SSCP) analysis, heteroduplex (HD) analysis
or denaturing gradient gel electrophoresis (DGGE)
method and more latterly DNA sequencing allowed the
establishment of mutation databases. At the present
time, the best APC gene mutation database resides at
the Institute of Medical Genetics in Cardiff (http://www.
hgmd.cf.ac.uk/ac/index.php) as it provides a comprehen-
sive list of mutations for the majority of reported genes
[24]. At present, information exists for 858 different
APC mutations have been reported to the HGMD data-
base. Small deletions constitute the highest proportion
of APC mutations. A total of 356 mutations have been
described and, in the majority, they lead to a change in
the reading frame and the creation of a premature ter-
mination codon. Much rarer are large deletions (54),
splice site mutations (49), small deletions combined with
insertions (17), large insertions (7), complex rearrange-
ments (6) and 3 mutations were observed in regulatory
sequences. 235 mutations were represented as substitu-
tions leading to changes in amino acids or to the devel-
opment of the stop codon at the mutation site. The total
of 131 small insertions have been described so far. In the
case of substitutions, which constitute 30% of all muta-
tions, the stop codon arises at the mutation site, whereas
in the case of deletions or insertions, which constitute
68% of mutations, the STOP codon occurs downstream
of the mutation as a result of a shift in the reading
frame. There is a region in the gene characterised by an
increased frequency of mutations called the MCR
(mutation cluster region) which encompasses codons
1055–1309 and 23% of all germline mutations occur in
this region. In addition, among germline mutations, an
increased frequency of the following three mutations has
been observed: deletions of 5 bp in codone 1309 (10%),
deletions of 5 bp in codone 1061 and deletions of 4 bp
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found in the 5’ region of exon 15 of the APC gene. A
characteristic FAP attribute is loss of heterozygosity
(LOH) in the APC in adenomas developing as a result of
somatic mutation in the second allele. The frequency
distribution of these mutations differs from germline
mutations. Up to 60% of somatic mutations are situated
in the fragment, which encompasses 8% of the gene be-
tween codons 1286 and 1513. Somatic mutations occur
in two hot spots in codon 1309 and codon 1450. Muta-
tions in APC also occur in cases of large intestinal
tumours unrelated with polyposis. In “sporadic” colorec-
tal cancer (CRC) these neoplasms occur as a result of a
mutation in one of the APC alleles followed by a loss of
heterozygosity as a result of somatic mutations. In the
case of the Lynch syndrome (HNPCC), the process is ac-
celerated by inherited mutations in DNA repair genes
[25]. According to the latest investigations, it is not ne-
cessary for LOH to occur in APC in order for the initi-
ation of colorectal cancer to take place. In half of the
sporadic cases of CRC in which no changes in APC
occur, tumour development is associated with heterozy-
gote mutations in the β-catenin gene (CTNNB1) [26].
These mutations result in the switching off of the APC
regulatory function leading to β-catenin accumulation
and, hence, expression of the MYC gene and develop-
ment of CRC.
Attempts have been made to determine whether a
genotype phenotype correlation exists that can be asso-
ciated with the clinical course of the disease. It has been
reported that the occurrence of the stop codon upstream
of codon 157 is associated with a decreased number of
polyps and a milder disease course. A typical disease
course associated with hundreds to thousands of aden-
omas can be expected when the stop signal occurs be-
tween codons 169 and 1600. Mutations found between
codons 1403 and 1587 lead to the diversification of
symptoms that include osteomas, desmoid tumours and
CHRPEs. The occurrence of desmoid tumours is also as-
sociated with mutations in the region between codons
1445 and 1578. Mutations at the 3’ end of APC result in
a differing picture of disease both with regard to polyp
numbers and the occurrence of extra-colonic symptoms.
Progression of morphological and genetic changes in
familial adenomatous polyposis
The inheritance of the mutated allele of the APC gene
does not result in a clinical picture of the disease. The
appearance of clinical symptoms is associated with the
sequence of further events in the cell. Both in the case
of FAP and HNPCC, cells are characterised by a very
high risk of loss of the wild type APC allele. Gene dele-
tions in tumours are observed to occur in regions associ-
ated with proliferation located on 5q (APC, MCC), 17p(TP53) and 18q (SMAD4) chromosomes, while point
mutations are often found within the K-RAS proon-
cogene. In the case of FAP, the risk of loss of heterozy-
gosity is very high because one of the alleles is inherited
in a mutated form. The loss of a series of genes associate
with cell-cell recognition, DNA damage response and
cell proliferation must occur prior to tumour develop-
ment. It is not the order that is important, rather the
total number of events. Of particular interest is the ne-
cessity of APC loss prior to carcinoma development. It
has been reported that a series of genes can be lost (P53,
MCC, k-RAS and DCC) but without APC tumour devel-
opment does not occur [6]. Once APC is lost, tumour
development is inevitable.
Structure and location of the MUTYH gene
The MUTYH gene (MutY, e. coli, Homolog) is a
homologue of a bacterial mutY gene involved in the
repair of oxidative DNA damage. Alternatively, the
MUTYH gene is frequently referred to as hMYH or
MYH but the above names are considered as inappropri-
ate due to their being used to describe myosin genes. In
man, the MUTYH gene was first described in 1996. It
encompasses 7100 bp on chromosome 1 in the region of
p34.3-p32.1 and consists of 16 exons. None of the 15 in-
trons of the MYH gene exceed 200 bp. The gene en-
codes a 535-amino acid protein, which is 41% identical
with the mutY protein found in E. coli not. Most fre-
quently, two substitutions Y165C and G382D occur
which are observed in 80% of patients with mutations of
both gene alleles [5,27,28].
Phenotype mutation in the APC gene (Phenotype
associated with mutations in the APC gene)
Familial adenomatous polyposis (FAP) (MIM 175100)
Familial polyposis of the large intestine (FAP) is a predis-
position inherited in an autosomal dominant manner for
the occurrence of numerous polyps in the large intes-
tine. Symptoms in the form of numerous (hundreds or
thousands) polyps in the mucous of the large intestine
appear towards the end of the second decade of life.
Average age of polyp incidence is 15 years of age [25].
The polyps are characterized by large potential for the
development towards malignant tumour. Malignancy
can occur from late childhood onwards. The first symp-
toms of FAP are diarrhea and blood in the stool. Weight
loss and weaknesses occur after the development of ad-
vanced tumour. The incidence of the FAP disorder is
one per 10000 newborns. There are high levels of het-
erogeneity with regard to the number and timing of the
occurrence of polyps. The typical disease course is
characterised by the occurrence of over 100 polyps,
which appear most frequently in the second decade of
life and can co-occur with lymphoid polyps [29]. The
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ters reaching up to several centimetres. Tubular-villous
and villous adenomas are also quite frequent [30]. More-
over, intestinal polyps can also occur as flat tubular
polyps [31]. One of the typical features of polyposis is a
severe phenotype in which the number of polyps exceed
one thousand [32]. Severe FAP is characterised by an
earlier age of tumour occurrence, on average 34 years of
age, and a more frequent occurrence of extra-colonic
disease.
Extra colonic features of FAP vary considerably and
can include:
 Retinal pigment discolouration of the eye fundus
(congenital hypertrophy of the retinal pigment
epithelium - CHRPE) is has been tentatively
associated with the location of the mutation in the
APC gene. CHRPE has been reported to occur in
more than half of the carriers of the mutation in the
APC gene [33], however, this remains to be
confirmed. Retinal hyperpigmentation has not been
shown to occur if the product of the mutated gene
is smaller than 50 kDa and exon 9 is considered as
the boundary between mutations causing or not
causing discolouration. In the 3’ region of the APC
gene, codon 1387 is the boundary of the occurrence
of hyperpigmentation [34]. The length of the
product affects the discolouration picture. Gene
protein products less than 1014 amino acids long
present a picture of a small round pigmented spot
or large round pigmented spot. Protein products
encompassing at least 1014 amino acids are
associated with an increased incidence of the
remaining two types of retinal changes in fundus,
i.e. oval pigmented with a surrounding halo and
large round de-pigmented spot [35]. Codon 1014 is
the binding site of two cytoplasmic proteins: α and
β-catenin, which are important for protein active in
the adhesion of E-cadherin cells. Products longer
than 1014 amino acids can bind with these proteins,
which may affect the change of phenotype
discolouration [36]. Retinal hyperpigmentation is
used as a carrier state marker of the mutated allele,
although the development of molecular biology
techniques as well as incomplete penetrance has
reduced its significance.
 Changes in dentition involving, most frequently, the
appearance of supernummery teeth as well as
osteomas and changes in tooth structure,
 Polyps in upper segments of the gastrointestinal
tract. Duodenal and gastric polyps can occur in the
form of polyps of the stomach fundus or adenomas
[37]. Stomach polyps occur in approximately 50% of
FAP patients and do not have a high potential toform neoplasms. Adenomas observed in 6% of cases
form neoplasms even less frequently than polyps of
the stomach fundus [38]. Duodenal polyps are
diagnosed in 33% to 44% of FAP patients [39-41],
although a group of probands was described where
the frequency of duodenal polyps reached 80% [41].
Polyps are usually situated in the descending part of
the duodenum. In some of patients, larger polyps
are observed in the vicinity of the larger papilla of
the duodenum.
 Desmoid tumours are observed in about 10% FAP
patients and its appearance usually follows a surgical
operation [42]. In comparison with general
population, desmoid tumours are observed at
significantly increased rates in FAP patients.
Moreover, gender is also found to modify the
occurrence frequency; the disease occurs less
frequently in men with FAP than in women at a
ratio of 1: 3 [42,43].
 Thyroid gland tumours are observed in FAP with
more than 94% of cases being diagnosed in women
[44-46].
 Central nervous system neoplasms occur with low
frequency of about 1% and they are usually gliomas.
The occurrence of these tumours together with FAP
symptoms in the intestine is described as Turcot’s
syndrome (MIM#276300) [47-49]. Brain cancer in
FAP is associated more with the occurrence of the
locus modifying the disease course than with a
specific spectrum of mutations in the APC gene.
This is exemplified by the fact that in cases of
sporadic brain gliomas or medulloblastomas no
mutations in the APC gene have been reported
[50,51].
 Hepatoblastomas are rare neoplasms occurring in
children. Increased risk of occurrence of these
cancers in APC mutation carriers were observed but
the incidence did not exceed 1% [32,52,53].
Attenuated form of familial adenomatous polyposis coli
(AAPC)
The mild form of the large intestine familial polyposis
(attenuated adenomatous polyposis coli – AAPC) is
characterised by the occurrence of a small number of
polyps, from several to one hundred. From among par-
enteral symptoms, the occurrence of the stomach fundus
polyps is rare [34]. This form of familial intestinal polyp-
osis is connected with the occurrence of mutation at the
5’ end of the APC gene. It is assumed that codon 159 is
the boundary between AAPC and FAP causing muta-
tions, although it is difficult to establish this boundary
unequivocally because this form of the disease occurred
also in cases when the mutation led to the formation of
the Stop codon in exon 9 of the APC gene [34].
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Recessive polyposis (MIM 608456) / MAP (MUTYH
associated polyposis).
Recessive polyposis is an autosomal recessive predis-
position for the occurrence of numerous polyps in the
large intestine whose numbers are smaller than in the
case of FAP and do not exceed 100 [54]. Cancer risk in-
cidence increase in mutation carries of both MUTYH
gene alleles and it is 93 times higher in comparison with
general population; intestinal neoplasm appears nearly
always before the 60th year of life [55]. Moreover, it was
observed that mutations of both MUTYH gene alleles
increase the risk of endometrial tumours which, at a
small number of polyps or their absence, may make the
phenotype resemble Hereditary Nonpolyposis Colorectal
Carcinoma (HNPCC) [55]. Differences in the extent of
pathogenic symptoms are also observed in the relatives
of carriers of the same mutations [55].
Turcot syndrome (MIM 276300)
The Turcot syndrome comprises the co-occurrence of
neoplasms of the gastrointestinal tract and malignant
carcinoma of the central nervous system. In 1991, two
forms of the disease were identified: one inherited in an
autosomal dominant manner with the occurrence of
medulloblastoma at young age and intestinal FAP
symptoms and the other inherited autosomally in a re-
cessive manner with the occurrence of glioblastoma and
HNPCC attributed to elderly patients in the large intes-
tine [56]. It was observed in Turcot syndrome that in
the case of patients with a mutation in the APC gene, in
79%, a medulloblastoma appeared, whereas in patients
with the intestinal traits indicating mutations in the
DNA repair genes – a glioma developed. Mutations
identified in the APC gene exhibit heterogenity. No spe-
cific region in the APC gene was identified associated
with the occurrence of the Turcot syndrome.
FAP molecular diagnosis
DNA isolated from peripheral blood cells is used for the
molecular analysis of APC gene. The search for
mutations employs screening methods that include het-
eroduplex analysis (HA), single-stranded conformation
polymorphism (SSCP) and high resolution melting
(HRM). HRM is one of the more novel techniques
employed in screening investigations which allows iden-
tification of small sequence changes within the examined
fragments [57]. The mode of action of the method is
based on monitoring the behaviour of DNA fragments,
amplified earlier, during the denaturation process. The
analysis is enabled by the presence in the reaction mix-
ture of a fluorescent dye which intercalates only the
double-stranded DNA sending a strong fluorescent sig-
nal making it possible to observe the melting process,i.e. conversion of dsDNA into ssDNA in the course of
denaturation. The comparison of melting profiles of in-
dividual fragments with one another makes it possible to
select those that indicate differences in the course of de-
naturation which, at the same time, reflect changes in
the sequence. HRM is a screening technique and fails to
provide accurate information about changes in the se-
quence and, therefore, all atypical melting profiles re-
quire confirmation by sequencing. Nevertheless, high
sensitivity of the method, according to some researchers,
reaching even 100%, allows considerable reduction of se-
quencing numbers and, consequently, of the cost of ana-
lyses, at the same time maintaining and sometimes even
increasing the identification effectiveness of mutations in
comparison with earlier screening methods.
An important issue is the detection of large
rearrangements in the APC gene. Searching for large
changes concerning particular exons or even entire
genes was greatly simplified when in 2002, Schouten de-
scribed Multiplex Ligation-dependent Probe Amplifica-
tion (MLPA) the quantitative analysis of up to 40 DNA
fragments amplified with identical primers in the same
reaction tube [58]. Since then, there has been a rapid
development of this technique and the method is cur-
rently used in research on predispositions to hereditary
diseases, characteristic of cancer, methylation analysis,
RNA analysis and pharmacogenetics.
The method is based on hybridization of probes halves
to selected fragments of genomic DNA, their ligation
and amplification. This allows the quantitative evalu-
ation of PCR products. Hybridization of the probes to a
specific DNA fragment opens up possibilities for the
study of known mutations that occur with increased fre-
quency in cases of certain diseases.
The MLPA kit P043 for the APC gene in addition to
probes for testing particular exons contains two probes
for the detection of mutations 3183-3187delACAAA and
3927-3931delAAAGA. These two mutations are, in
some populations even up to several percent of all
detected mutations in FAP patients. In our group of pa-
tients with FAP, these two mutations are present almost
in 15% of patients.
The next-generation sequencing opens new possibil-
ities in the search for mutations in the APC gene. This
method with target enrichment allows a detailed exam-
ination of the gene sequence. The advantage this method
is ability to detect of small mutations as well as those in-
volving several exons. Such tests have been developed.
One of them is ColoSeq, where the target enrichment
and mass sequencing allow test at the same time all of
the genes of suitability for FAP and HNPCC [59].
After the identification of mutation in the APC gene,
an analysis of inheritance of the mutated allele of the
APC gene is performed in all persons of the probands’
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are identified, indirect analysis can be applied that
examine the co-inheritance of conjugated markers [60].
Markers located close to the examined gene are applied
to investigate inheritance of the mutated allele. It is
recommended to apply several gene flanking markers to
avoid mistakes resulting from crossing-over between the
marker and the gene. Familial adenomatous polyposis
has been investigated in our country for over 15 years
now at the IHG PAS in Poznan. The established DNA
Bank of Polish patients suffering from familial polyposis
contains material from 600 families. Research results
have been presented in specialised journals [45,61]. Ap-
proximately 50% of FAP families without an identified
APC mutation pose a diagnostic problem. Some reports
indicate new research directions in this field. Dutch sci-
entists succeeded in identifying miRNAs, which regulate
APC gene expression. Target sequences for miRNA as
well as the location of 3 encoding genes were deter-
mined. The gene coding miR-135a-1 is located in the
first intron of the stabilin 1 gene STAB1 (3q21), whereasFigure 2 Molecular diagnostic of FAP.the gene coding miR-135a-2 is found in intron 5 of
the RMST gene coding the transcript associated with
rabdomyosarcoma (12q23) [62]. The miR-135b coding
gene is located on chromosome 1q32.1 in intron 1 of the
LEMD1 gene. miRNA precursors are made up of 93, 102
and 99 nucleotide sequences and can be found on
chromosome 3 - miR135a-1, on chromosome 12 miR-
135a-2 and chromosome 1 miR-135b, respectively. It
has been shown experimentally that in in vitro
miRNA system – miR135a and miR135b interact
with 3’UTR transcript of the APC gene and affect
the level of mRNA and, in this way, regulate APC
expression and consequently the Wnt proliferation
control pathway. Furthermore, it was observed that
increased quantities of miR-135a and miR-135b lead
to the reduction in the amount of mRNA of the
APC gene in neoplastic tumours of the intestine [63].
Examination of these sequences will increase our
knowledge about the genetic background of this dis-
ease and improve its diagnosis. The most recent re-
ports indicate the potential involvement of changes
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cause their impact on the correctness of expression
may be important.
FAP prophylaxis
At the present time patients at risk of disease are
screened by sigmoidoscopy every 12 months beginning
at puberty. This makes it possible to discover symptoms
long before the development of an invasive neoplasm.
Once polyps appear, the only effective measure to
prevent the occurrence of the malignant disease is to re-
move surgically the entire colon and rectum. Prophylac-
tic colectomy performed at an appropriate age prolongs
the life expectancy of FAP patients, on average, from 45
to over 60 years of age.
During surgery, the entire large intestine is removed
and a J pouch is formed using the small intestine. The
mucous membrane of the small intestine exhibits con-
siderable plasticity and it becomes morphologically simi-
lar to the mucous membrane of the large intestine.
Surgery is currently the only possibility to improve the
life expectancy of patients, although very effective, it
causes serious morbidity, especially when performed at
advanced stages of disease when the anus must also be
removed. There is much interest in alternative ap-
proaches where there is an ongoing assessment of the
impact of food composition and non-steroid anti-
inflammatory drugs shown to reduce the numbers of in-
testinal adenomas. Interestingly, resistant starch con-
sumption and the incidence of large intestinal tumours
demonstrate an inverse correlation and animal studies
have shown some promise. A number of mouse models
have been developed, including a functional/knock-out
gene APCΔ716 [64]. These mice are heterozygotes for
the APC mutation at codon 716 which results in a typ-
ical disease course in terms of polyp appearance occur-
ring at about the third week of life in the mouse.
Homozygote mutation carriers are embryologically le-
thal. Diets containing high levels of starch and low in fat
did not affect the frequency of disease but did reduce by
64% polyp numbers as well as their size in this mouse
model. Numbers of polyps are also reduced by the admin-
istration of non-steroid anti-inflammatory drugs. The ap-
plication of Aspirin, Piroxicam and Sulindac reduced the
number of polyps in the large intestine of experimental
mice with mutated APC from 40% to 60% [63].
Attempts are also being undertaken to employ gene
therapy for FAP treatment. The fact that the illness is
preconditioned by a mutation in one gene facilitates sig-
nificantly attempts to repair the error. Using liposomes as
vectors, a complete functional APC gene was introduced
into a colorectal cancer cell (SW480) line derived from the
large intestine with a mutated APC gene. The transfer of
APC led to the expression of the correct APC in SW480cells after 72 hours and it was observed for a period of one
week at a level guaranteeing a biological effect.
Neoplastic diseases of the large intestine are well
recognised but it remains necessary to understand all
factors influencing the initiation and development of
tumours as well as possible interactions between these
factors. Studies of mutations occurring in the course of
the development of neoplastic diseases will make it pos-
sible to select the most affective prophylactic method or
minimisation of pathologic consequences.Competing interests
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